VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

03 Apr 2025 07:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Mar 2025 15:28:05 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

27 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

26 Feb 2025 07:25:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

13 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Dec 2024 17:29:08 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

08 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

29 Oct 2024 19:22:02 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

28 Oct 2024 16:37:30 By Nasdaq GlobeNewswire

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

26 Oct 2024 18:30:00 By Nasdaq GlobeNewswire